公式財務諸表に基づく売上高、利益、キャッシュフローの推移。
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→
| 損益計算書 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 売上高合計 | DKK 329.4B | DKK 309.1B | DKK 290.4B | DKK 232.3B | DKK 177.0B | DKK 140.8B | DKK 126.9B | DKK 122.0B | DKK 111.8B | DKK 111.7B | DKK 111.8B | DKK 107.9B | DKK 88.8B | DKK 83.6B | DKK 78.0B | DKK 66.3B | DKK 60.8B | DKK 51.1B | DKK 45.7B | DKK 41.9B | DKK 38.8B |
| 売上総利益 | DKK 265.7B | DKK 250.3B | DKK 245.9B | DKK 196.5B | DKK 148.5B | DKK 117.1B | DKK 106.0B | DKK 101.9B | DKK 94.2B | DKK 94.1B | DKK 94.6B | DKK 91.7B | DKK 74.2B | DKK 69.4B | DKK 64.6B | DKK 53.8B | DKK 49.1B | DKK 40.6B | DKK 35.5B | DKK 32.1B | DKK 29.2B |
| 売上総利益率 % | 80.7% | 81.0% | 84.7% | 84.6% | 83.9% | 83.2% | 83.5% | 83.5% | 84.2% | 84.2% | 84.6% | 85.0% | 83.6% | 83.1% | 82.7% | 81.0% | 80.8% | 79.6% | 77.8% | 76.6% | 75.3% |
| 営業利益（EBIT） | DKK 142.1B | DKK 127.7B | DKK 128.3B | DKK 102.6B | DKK 74.8B | DKK 58.6B | DKK 54.1B | DKK 52.5B | DKK 47.2B | DKK 49.0B | DKK 48.4B | DKK 49.4B | DKK 34.5B | DKK 31.5B | DKK 29.5B | DKK 22.4B | DKK 18.9B | DKK 14.9B | DKK 12.4B | DKK 9.0B | DKK 9.1B |
| 営業利益率 % | 43.1% | 41.3% | 44.2% | 44.2% | 42.3% | 41.6% | 42.6% | 43.0% | 42.2% | 43.8% | 43.3% | 45.8% | 38.8% | 37.7% | 37.8% | 33.7% | 31.1% | 29.2% | 27.2% | 21.4% | 23.5% |
| 当期純利益 | DKK 116.4B | DKK 102.4B | DKK 101.0B | DKK 83.7B | DKK 55.5B | DKK 47.8B | DKK 42.1B | DKK 39.0B | DKK 38.6B | DKK 38.1B | DKK 37.9B | DKK 34.9B | DKK 26.5B | DKK 25.2B | DKK 21.4B | DKK 17.1B | DKK 14.4B | DKK 10.8B | DKK 9.7B | DKK 8.5B | DKK 6.5B |
| 純利益率 % | 35.4% | 33.1% | 34.8% | 36.0% | 31.4% | 33.9% | 33.2% | 31.9% | 34.5% | 34.1% | 33.9% | 32.3% | 29.8% | 30.1% | 27.5% | 25.8% | 23.7% | 21.1% | 21.2% | 20.4% | 16.7% |
| EBITDA | — | DKK 156.7B | DKK 147.9B | DKK 114.6B | DKK 76.8B | DKK 65.4B | DKK 59.3B | DKK 54.4B | DKK 51.6B | DKK 52.0B | DKK 51.1B | DKK 46.5B | DKK 37.6B | DKK 35.4B | DKK 30.6B | DKK 24.9B | DKK 21.3B | DKK 17.8B | DKK 14.9B | DKK 12.0B | DKK 11.3B |
| 1株当たり利益（EPS） | DKK 26.20 | DKK 23.03 | DKK 22.63 | DKK 18.62 | DKK 12.22 | DKK 10.37 | DKK 9.00 | DKK 8.19 | DKK 7.97 | DKK 7.69 | DKK 7.48 | DKK 6.76 | DKK 5.03 | DKK 4.67 | DKK 3.88 | DKK 3.00 | DKK 2.46 | DKK 1.78 | DKK 1.55 | DKK 1.34 | DKK 1.00 |
| 発行済株式数（百万株） | — | 4,448M | 4,463M | 4,495M | 4,545M | 4,606M | 4,680M | 4,757M | 4,849M | 4,956M | 5,070M | 5,157M | 5,260M | 5,387M | 5,517M | 5,701M | 5,855M | 6,043M | 6,226M | 6,357M | 6,459M |
出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。
貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は NVO のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/NVO
本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。
About TickerBase · Data methodology & sources · Privacy · Terms